<DOC>
	<DOCNO>NCT02966353</DOCNO>
	<brief_summary>This study treatment ruxolitinib patient present transfusion dependent independent anemia 10 mg BID start dose subsequent titration depend safety efficacy .</brief_summary>
	<brief_title>Efficacy Safety Ruxolitinib Treatment Anemic Myelofibrosis Patients .</brief_title>
	<detailed_description>This study treatment ruxolitinib patient present transfusion dependent independent anemia screen define hemoglobin &lt; 10 g/dL 10 mg BID start dose subsequent titration depend safety efficacy . This dose approach anemic MF patient systematically study prospective multicenter phase II open label single arm trial determine level spleen length reduction symptom improvement consistent report previous clinical trial ruxolitinib patient anemia dos accord platelet count moment treatment initiation , whether low start dose titration approach may minimize initial hemoglobin platelet decline transfusion requirement .</detailed_description>
	<mesh_term>Primary Myelofibrosis</mesh_term>
	<mesh_term>Polycythemia</mesh_term>
	<mesh_term>Polycythemia Vera</mesh_term>
	<mesh_term>Thrombocytosis</mesh_term>
	<mesh_term>Thrombocythemia , Essential</mesh_term>
	<criteria>Written informed consent must obtain prior screen procedure . 1 . Male female patient age ≥ 18 year age . 2 . Patients must diagnose PMF , accord 2016 revise International Standard Criteria , PPV MF PETMF , irrespective JAK2 mutation status . 3 . Patients palpable splenomegaly equal great 5 cm leave costal margin . 4 . Patients hemoglobin less 10 g/dL 5 . Patients history transfusion must document transfusion record previous 12 week baseline . 6 . Patients ECOG performance status 0 , 1 , 2 . 7 . Patients peripheral blood blast percentage count &lt; 10 % . 8 . Patients must recover stabilize sufficiently adverse drug reaction associate prior treatment begin treatment ruxolitinib . 1 . Patients prior treatment JAK1 JAK2 inhibitor . 2 . Patients know hypersensitivity ruxolitinib JAK1/JAK2 inhibitor , excipients . 3 . Patients eligible hematopoietic stem cell transplantation ( suitable candidate suitable donor available ) . 4 . Patients inadequate bone marrow reserve baseline demonstrate least one following : 1 . ANC ≤ 1,000/µL . 2 . Platelet count &lt; 50,000/µL without assistance growth factor , thrombopoietic factor platelet transfusion . 3 . Hemoglobin count ≤ 6.5 g/dL despite transfusion . 5 . Patients severely impaired renal function define : Creatinine clearance le 30 mL/min . 6 . Patients inadequate liver function define : 1 . Total bilirubin ≥ 2.5 x ULN subsequent determination direct bilirubin ≥ 2.5 x ULN ; 2 . Alanine aminotransferase ( ALT ) &gt; 2.5 x ULN ; 3 . Aspartate aminotransferase ( AST ) &gt; 2.5 x ULN . 7 . Patients treat concurrently strong ( potent ) systemic inhibitor inducer CYP3A4 time Screening . 8 . Presence active bacterial , fungal , parasitic , viral infection require therapy . 9 . Known history human immunodeficiency virus ( HIV ) infection immunodeficiency syndrome Xlinked agammaglobulinemia common variable immune deficiency . 10 . Acute viral hepatitis active chronic hepatitis B C infection . Patients inactive chronic infection ( without viral replication ) enrol 11 . History progressive multifocal leukoencephalopathy . 12 . Impairment gastrointestinal ( GI ) function GI disease may significantly alter absorption ruxolitinib . 13 . History current diagnosis uncontrolled significant cardiac disease , include follow : 1 . Myocardial infarction within last 6 month 2 . Uncontrolled congestive heart failure 3 . Unstable angina within last 6 month 4 . Clinically significant ( symptomatic ) cardiac arrhythmia ( e.g . bradyarrhythmias , sustain ventricular tachycardia , clinically significant second third degree AV block without pacemaker ) 14 . Significant concurrent , uncontrolled medical condition , investigator 's opinion , would jeopardize safety patient compliance protocol . 15 . Patients undergoing treatment another investigational medication treat investigational medication within 30 day 5 halflives ( whichever longer ) prior first dose study drug . 16 . Patients history malignancy past 3 year , except treat early stage squamous basal cell carcinoma . 17 . Patients unable comprehend unwilling sign ICF . 18 . Pregnant nursing ( lactate ) woman 19 . Women childbearing potential , defined woman physiologically capable become pregnant , unless use highly effective method contraception throughout study duration inclusive 30 day safety follow .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Ruxolitinib</keyword>
	<keyword>anemia</keyword>
	<keyword>Primary Myelofibrosis ( PMF )</keyword>
	<keyword>Post-Polycythemia Vera-Myelofibrosis ( PPV-MF )</keyword>
	<keyword>Post-Essential Thrombocythemia Myelofibrosis ( PET-MF )</keyword>
</DOC>